StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab profit margin

Profit margin (net margin) is net income as a percentage of revenue.

BioNexus Gene Lab's profit margin for the twelve months ending Jun 30, 2026 was -82.4%. For fiscal 2025 it was -40.2%, against -16.8% the year before. The highest annual figure on record is 12.5% in fiscal 2018.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-40.2%−23.4
FY2024Dec 31, 2024-16.8%+10.1
FY2023Dec 31, 2023-26.9%−23.6
FY2022Dec 31, 2022-3.3%−8.9
FY2021Dec 31, 20215.6%−4.0
FY2020Dec 31, 20209.6%+203.7
FY2019Dec 31, 2019-194.1%−206.6
FY2018Dec 31, 201812.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-376.1%−348.9
Q1 FY2026Mar 31, 2026-2379.7%−2350.5
Q4 FY2025Dec 31, 2025-214.2%−200.4
Q3 FY2025Sep 30, 2025-27.9%+23.3
Q2 FY2025Jun 30, 2025-27.3%−37.3
Q1 FY2025Mar 31, 2025-29.2%−24.8
Q4 FY2024Dec 31, 2024-13.8%−27.4
Q3 FY2024Sep 30, 2024-51.1%+51.0
Q2 FY2024Jun 30, 202410.1%+20.2
Q1 FY2024Mar 31, 2024-4.4%−1.5
Q4 FY2023Dec 31, 202313.6%+19.1
Q3 FY2023Sep 30, 2023-102.2%−99.2
Q2 FY2023Jun 30, 2023-10.1%−4.5
Q1 FY2023Mar 31, 2023-2.9%−3.5
Q4 FY2022Dec 31, 2022-5.5%−8.3
Q3 FY2022Sep 30, 2022-3.0%−11.3
Q2 FY2022Jun 30, 2022-5.6%−6.5
Q1 FY2022Mar 31, 20220.6%−9.3
Q4 FY2021Dec 31, 20212.7%+7.0
Q3 FY2021Sep 30, 20218.3%+0.7
Q2 FY2021Jun 30, 20210.9%+4.2
Q1 FY2021Mar 31, 20219.8%−25.0
Q4 FY2020Dec 31, 2020-4.2%+170.3
Q3 FY2020Sep 30, 20207.6%+98.7
Q2 FY2020Jun 30, 2020-3.2%+322.0
Q1 FY2020Mar 31, 202034.8%+253.7
Q4 FY2019Dec 31, 2019-174.5%+494.9
Q3 FY2019Sep 30, 2019-91.1%+6.0
Q2 FY2019Jun 30, 2019-325.2%−289.8
Q1 FY2019Mar 31, 2019-218.8%–
Q4 FY2018Dec 31, 2018-669.4%–
Q3 FY2018Sep 30, 2018-97.1%–
Q2 FY2018Jun 30, 2018-35.5%–

More BioNexus Gene Lab figures

See a number that looks wrong?